Introduction
Cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) therapy each improve survival in appropriately selected patients with heart failure. 1 Implantable cardioverter-defibrillator therapy reduces the risk of sudden arrhythmic death, whereas the mortality benefit of CRT is related, in part, to favourable left ventricular reverse remodelling with related attenuation of both heart failure death as well as ventricular arrhythmias. 2, 3 As guideline indications for each device therapy frequently overlap, 4 ICD implantation is often performed in conjunction with CRT (CRT-D). 5 Despite the overall efficacy of CRT and ICD therapy, there is an expanding recognition that their benefit may not be uniform. For example, the survival benefit of ICD therapy may be nullified in the context of increasing comorbidity burden and competing modes of non-arrhythmic death. 6 Likewise, the efficacy of CRT may be attenuated in patients with comorbidities which mitigate effective pacing (e.g. atrial fibrillation, AF) or blunt remodelling (e.g. ischaemic cardiomyopathy). 7 Of the myriad predictors of CRT efficacy, female sex has been consistently associated with greater reverse remodelling and improved survival. 8 Despite this, women are significantly less likely than men to undergo CRT and ICD implantation, 9 although the basis for this underutilization remains poorly understood.
In this study, we utilized the National Inpatient Sample to evaluate sex differences in 311 009 individuals undergoing inpatient CRT implant in the United States between 2006 and 2012. Our aims were to (1) assess sex differences in CRT implant type (CRT-D, CRT-P) stratifying by predictors of device efficacy and (2) identify and compare predictors of CRT implant type in men and women. (3) Finally, we examine temporal trends in CRT device selection stratified by sex, with comparison to sex-specific trends in 423 507 individuals undergoing ICD-only implantation.
Methods

Data source
The National Inpatient Sample (NIS) is the largest publicly available allpayer inpatient health care database in the United States, yielding national estimates of diagnoses, procedure utilization, and outcomes for hospital inpatient stays. 10 The database contains a nationally representative sample from more than 7 million hospitalizations annually. Applying sample weights provided by NIS, the database projects estimates for more than 36 million hospitalizations annually. The NIS provides data on patient demographics, in-hospital clinical outcomes, hospital characteristics, and hospital charges. Federal hospitals are not included in the NIS. Quality control and validation of the NIS are performed by the Agency for Healthcare Research and Quality (AHRQ; Rockville, MD). The database was provided with de-identified patient information and thus was deemed exempt from institutional review by the Human Research Committee at Massachusetts General Hospital.
Study sample
We identified all adults > _18 years old who received a CRT device during a hospitalization between 1 January 2006 and 31 December 2012. CRT was defined by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes for CRT-P (00.50) and CRT-D (00.51). These two ICD-9-CM codes identify procedures where a total CRT system is implanted and do not identify CRT generator replacement. Sex was documented on all except 77 patients (99.98%). In sensitivity analysis, we additionally examined all adults > _ 18 years old who underwent ICD implantation (excluding CRT-D) during the same time period. ICD was defined by ICD-9-CM code 37. 94 .
Covariates and device efficacy scores
Demographic covariates of interest included age, sex, race/ethnicity, primary insurance type (Medicare, Medicaid, Private, and other), and income quartile. Race/ethnicity was reclassified as non-Hispanic white, nonHispanic black, other (Hispanic, Asian, and Native American), and missing. Other covariates included hospital type (rural, urban non-teaching, and urban teaching), type of admission (elective vs. acute), geographic region, and year of hospital discharge. Cardiovascular comorbidities were identified by ICD-9-CM codes and included coronary artery disease, nonischaemic cardiomyopathy, history of ventricular arrhythmia or cardiac arrest, AF, left bundle branch block (LBBB), and complete atrio-ventricular (AV) block. Non-cardiovascular comorbidity burden was assessed using the Elixhauser comorbidity measure, which was originally developed using administrative data relying on the ICD-9-CM coding manual for 30 comorbidities. 11 In this study, Elixhauser comorbidities were generated from ICD-9-CM diagnosis codes using the AHRQ Comorbidity Software. 12 Of note, cardiomyopathy, chronic kidney disease, and history of ventricular arrhythmia were removed from the comorbidity score in order to be analysed independently, and hence, the total number of Elixhauser comorbidities analysed was 27. ICD-9-CM codes used in the data analysis are listed in (see Supplementary material online, Table S1 ).
To assess the impact of predicted device efficacy on type of CRT implantation, we generated two morbidity-based scores previously shown to be associated with CRT and ICD efficacy. An ICD efficacy score was comprised of seven comorbidities (ischaemic heart disease, chronic kidney disease, diabetes, chronic pulmonary disease, AF, peripheral vascular disease, tobacco use) previously shown to be associated with reduced ICD efficacy in patients with heart failure. 6, 13, 14 For this study, the ICD efficacy score (range 0-7) was reclassified as 0, 1-2, > _3 given previous studies suggesting that the survival benefit of ICD implant was nullified in the presence of > _ 3 of the identified comorbidities. 6 A CRT response score was comprised of four clinical conditions known to be associated with left ventricular reverse remodelling after CRT implant: non-ischaemic heart disease, LBBB, absence of chronic kidney disease, and absence of AF. 8, 15, 16 The sum of the CRT response variables (range 0-4) was classified as 0, 1-2, or > _3. While female sex is an established predictor of reverse remodelling following CRT, 8 we excluded sex from the CRT response score to allow for direct comparability of CRT response scores between men and women. Exclusion of sex from the CRT response score would underestimate the likelihood of reverse remodelling in women, therefore yielding a conservative estimate by biasing any identified sex differences towards the null.
Statistical analyses
Frequencies, proportions and 95% confidence intervals (CI) were calculated and weighted to reflect national estimates using inverse sampling weights provided by NIS. Comprised of seven comorbidities associated with increased mortality and reduced ICD efficacy in patients with heart failure: ischaemic heart disease, atrial fibrillation, diabetes mellitus, chronic lung disease, chronic kidney disease, peripheral vascular disease, and smoking. Presence of > _ 3 comorbidities previously shown to negate survival benefit of primary prevention ICD 6 . 
Results
Baseline characteristics
The baseline characteristics of the 311 009 inpatient CRT implants between 2006 and 2012 in the United States are shown in Table 1 .
In keeping with a contemporary cohort of patients undergoing CRT, the majority of the study cohort was > _ 65 years of age (N = 222 696; 71.6%). The most prevalent non-heart failure comorbidities were hypertension, diabetes mellitus, and chronic kidney disease. Approximately one-third of patients had > _ 3 comorbidities associated with reduced ICD efficacy and a similar proportion had > _ 3 comorbidities associated with CRT response. When stratified by sex, there were significant differences in demographic and clinical characteristics ( Table 1) . Men undergoing CRT were more likely to be white (64.9 vs. 59.4%, P < 0.001) and were more likely to be undergoing ICD for secondary prevention (i.e. history of ventricular arrhythmia and/or cardiac arrest) (27.2 vs. 20 .1%, P < 0.001) compared to women. In contrast, women were more likely to have > _ 3 predictors of CRT response (47.3 vs. 33.2%, P < P < 0.001) including non-ischaemic cardiomyopathy (53.6 vs. 38.2%, P < 0.001) and were less likely to have > _ 3 comorbidities associated with reduced ICD efficacy (27.0 vs. 37.3%, P < 0.001).
Sex differences in use of CRT-D
In the total cohort, there was a higher percentage of CRT-D use in men compared to women (88.6 vs. 80.1%, P < 0.001) and this excess proportion was consistently present in multiple subgroups ( Table 2) . The majority of both men and women with a secondary prevention indication for ICD (i.e. ventricular arrhythmia or cardiac arrest) underwent CRT-D implant (95.6 vs. 92.7%) and the sex difference in % CRT-D implant was similarly small in those with non-ischaemic cardiomyopathy and LBBB. In contrast, the difference in percentage of CRT-D use in men vs. women was greatest in those with AF (absolute D: þ18.6 [17.0 to 20.3 ]%) and was also increased in those with chronic kidney disease and those > _ 80 years of age (Table 2; Figure 1) .
We next assessed unadjusted sex differences in CRT-D implant within strata of predicted device efficacy ( Table 2) . Amongst those with the greatest predicted CRT efficacy (i.e. CRT response score > _3), more than 90% of men and women underwent CRT-D All comparisons between female and age male had P < 0. 05. b Comprised of seven comorbidities associated with increased mortality and reduced ICD efficacy in patients with heart failure: ischaemic heart disease, atrial fibrillation, diabetes mellitus, chronic lung disease, chronic kidney disease, peripheral vascular disease, and smoking. 
Predictors of CRT-D in men compared to women
We next assessed multivariable predictors of CRT implant type in men compared to women. As shown in Table 3 
Temporal trends in CRT-D implantation by sex
Finally, we assessed temporal trends in CRT implant type in men compared to women, with parallel assessment of sex trends in patients undergoing ICD-only ( Figure 2) . Baseline characteristics of patients undergoing CRT-D, CRT-P, and ICD-only are shown in (see Supplementary material online, Figure 2B) . In contrast, the percentage of CRT-D implants in those with > _ 3 CRT response predictors remained high for both women and men over the study period (P, for sex D in time trend = 0.48). Over the same time period, the proportion of women amongst ICDonly recipients was unchanged ( Figure 2C ), including when stratified by CRT response score ( Figure 2D ).
Discussion
In this study of greater than 300 000 CRT implants in the US between 2006 and 2012, men were significantly more likely to undergo CRT-D implant compared to women. Sex differences in CRT-D implantation were sensitive to comorbidities known to impact device efficacy. We find that sex differences increased significantly over the study period, despite greater predicted CRT and ICD efficacy in women compared to men. Taken together, these data highlight an expanding sex disparity in CRT implant type in the USA, and further identify potential opportunities to There is an expanding recognition that CRT and ICD efficacy may not be uniform in men compared to women. First, left ventricular reverse remodelling is postulated to be an important mechanism of survival benefit in CRT. 3 In our study, women were significantly more likely to have clinical characteristics associated with a greater likelihood of reverse remodelling, which is consistent with previous findings that women have improved survival following CRT implant compared to men. 17 Second, ICD benefit may be attenuated in the presence of competing modes of death and comorbidities associated with these competing risks may differ in men and women. 13, 14 In our study, women undergoing CRT were more likely to have a comorbidity profile associated with CRT and ICD benefit, which is in keeping with the sex distribution of clinical characteristics described in other contemporary CRT cohorts, including the European CRT Survey. 18 Consistent with these findings, others have identified similar and potentially superior survival following ICD implant in women compared to men. 19 Our group 5 has previously identified the presence of a sex differences in CRT implant patterns in the US and others have highlighted similar findings in Europe. 20 Our findings extend these previous observations in several ways. First, we assessed sex differences in several clinically relevant subgroups. In keeping with contemporary guidelines, 4 we observed consistently high and similar percentage of CRT-D device use among men and women with a secondary prevention indication for ICD (i.e. ventricular arrhythmia or cardiac arrest). Likewise, there was similarly minimal sex differences in patients with non-ischaemic cardiomyopathy. In contrast, we identified significant sex differences in CRT-D implant use in the presence of other Sex cardiac resynchronization therapy with implantable cardioverter defibrillators relevant subgroups including AF, chronic kidney disease, and the elderly. We would further highlight that sex remained a significant predictor of CRT device type even after adjusting for ICD indication and clinical risk factors, including non-ischaemic cardiomyopathy. Second, we explore the clinical implications of the identified sex differences by leveraging previous reports linking comorbidities with device efficacy. 6, 8 While >90% of both men and women predicted to have high likelihood CRT response underwent CRT-D implantation, the difference in CRT-D use in men vs. women increased significantly in those less likely to respond to CRT. Similarly, there were minimal sex differences in CRT-D implantation amongst those with the greatest predicted ICD efficacy, but a widening disparity in those with lower predicted ICD efficacy. By coupling comorbidity-specific sex differences in CRT-D implant with the established relationship between comorbidities and device efficacy, our findings highlight the clinical implications of these sex disparities.
We also show that the sex disparity in CRT implant type increased over the study period, and specifically in those predicted to have a lower likelihood of CRT response. Our temporal trend findings extend findings from a recent report which demonstrated static sex differences in ICD implantation between 2005 and 2009 in the US. 9 In contrast to previous ICD-only studies, 9 we leverage the simultaneous presence of patients with and without ICD implantation (i.e. CRT-D vs. CRT-P) available in the National Inpatient Sample database. As an internal control, we show that there was no evidence that our findings of a widening disparity were related to a secular decrease in ICD-only implantation amongst women. The similar distribution of comorbidities in ICD-only and CRT-D recipients suggests that our findings may be applicable to ICD-only recipients, generally, although additional investigation in ICD-eligible HF patients appears warranted.
Maximizing the benefit of CRT and ICD therapy in the everexpanding population of patients with heart failure will require improved alignment of device implantation with those most likely to benefit. The complexity of decision-making regarding ICD implantation at the time of CRT is further increased given that CRT associated improvements in LV function may attenuate both sudden arrhythmic death as well as non-sudden cardiac death. 2 Indeed, despite the established efficacy of ICD therapy in appropriately selected patients, there remains no direct comparison establishing the incremental efficacy of CRT-D compared to CRT-P alone. 21 While CRTrelated improvements in left ventricular function may attenuate risk of ventricular arrhythmias, we would note that anticipated ventricular response to CRT is not represented in guidelines regarding ICD implantation, 4 and that patients with reverse remodelling remain at risk for ventricular arrhythmias. 22 In addition, CRT-related reverse remodelling may also modify the risk of other 'competing modes of death' (e.g. heart failure death) 2 which, in turn, could influence the potential lifetime survival benefit of ICD therapy. 23 Taken together, our findings highlight the ongoing need to refine our understanding of the dynamic influence of CRT on modes of death after implant and furthermore, how such anticipated responses may influence sexspecific decision making at the time of CRT implant. Contemporary implant practices regarding CRT device selection differ by region, with a greater proportion of CRT-D implant in the US as compared to Europe. 5, 24 As suggested by the recent report from the CeRtiTuDe registry which identified an excess of nonarrhythmic death in those undergoing CRT-P, 25 27 Finally, the inclusion of an ICD in those undergoing CRT has significant clinical implications including the risk of device complications (15% at 3 years), increased healthcare utilization (battery depletion/need for generator change), and the deleterious clinical impact of inappropriate ICD therapy. 28 Viewed in this context, our findings highlight potentially divergent opportunities to 'narrow the gap' for more effective deployment of CRT-D. For example, in those with a low likelihood of ICD efficacy, the sex gap may be appropriately addressed by decreasing CRT-D implants in men unlikely to benefit (e.g. > _ age 80 with ischaemic heart disease and chronic kidney disease). Conversely, the sex disparity in CRT-D implantation for those with an intermediate probability of CRT response (e.g. 1-2 CRT response predictors) may be best addressed by targeted augmentation of CRT-D implant in women. Our data also highlight the need to better understand the influence of comorbidities and predicted device efficacy on patient-physician decision making at the time of device selection. Emerging literature supports the possibility of sex-specific differences in physician attitudes and patient preferences regarding trading quality of life and survival time. 29 Whether specific comorbidities influence such quality of life preferences differentially may warrant additional exploration.
Limitations
The findings of this study should be interpreted within the limitations of its study design. First, these data represent serial cross-sectional assessments and availability of longitudinal clinical and echocardiographic outcomes would offer a more robust understanding of the potential clinical consequences of the identified differences. Second, while there remains no consensus definition for CRT response, left ventricular reverse remodelling is a robust and specific metric of biventricular pacing therapy. 1 The selected measures of CRT response in our study have been consistently identified in systematic reviews and post-hoc analyses of randomized controlled trials in CRT. 1, 7 However, some proposed predictors of echocardiographic response after CRT implantation were not available (e.g. QRS duration, left ventricular lead location) and would have enhanced our ability to stratify the likelihood of reverse remodelling. To the extent that specific measures highlighted in recent consensus guidelines may identify greater device benefit in women as compared to men (e.g. QRS duration < 150 ms), 30 our findings would only be underestimating the sex disparities present within strata of predicted CRT efficacy. Third, our analyses relied on using ICD-9-CM diagnosis codes with known high specificity and lower sensitivity. 31 This likely explains the lower than expected prevalence of certain morbidities (e.g. 33% prevalence of LBBB). Other lifestyle factors considered in our study (e.g. tobacco smoking) have shown significant correlation with direct survey methods. 32 In addition, certain baseline characteristics (e.g. race) were unknown in a significant minority of patients, although we
